References
- Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
- Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9
- Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
- Amin A, Jhaveri M, Lin J. Hospital readmissions in US atrial fibrillation patients: occurrence and costs. Am J Ther 2013;20:143-50
- Johnson BH, Smoyer-Tomic KE, Siu K, et al. Readmission among hospitalized patients with nonvalvular atrial fibrillation. Am J Health Syst Pharm 2013;70:414-22
- Deitelzweig SB, Pinsky B, Buysman E, et al. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther 2013;35:1536-45
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361:1139-51
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011;365:883-91
- Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-2
- Cunningham A, Stein M, Chung C, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011;20:560-6
- Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014;63:891-900
- Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-72
- U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm [Last accessed 4 March 2015]
- Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in Medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42:112-18
- Amin A, Bruno A, Trocio J, et al. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs. warfarin or placebo in the U.S. J Med Econ 2015;18:399-409
- Joynt KE, Jha AK. A path forward on Medicare readmissions. N Engl J Med 2013;368:1175-7